

**BEFORE THE
MEDICAL BOARD OF CALIFORNIA
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

**In the Matter of the Accusation
Against:**

Emil Soorani, M.D.

**Physician's and Surgeon's
Certificate No. A 37184**

Respondent.

Case No.: 800-2015-011341


DECISION

The attached Stipulated Settlement is hereby adopted as the Decision and Order of the Medical Board of California, Department of Consumer Affairs, State of California.

This Decision shall become effective at 5:00 p.m. on February 11, 2022.

IT IS SO ORDERED: January 14, 2022.

MEDICAL BOARD OF CALIFORNIA



**Richard E. Thorp, M.D., Chair
Panel B**

1 ROB BONTA
Attorney General of California
2 ROBERT MCKIM BELL
Supervising Deputy Attorney General
3 CHRISTINA SEIN GOOT
Deputy Attorney General
4 State Bar No. 229094
California Department of Justice
5 300 So. Spring Street, Suite 1702
Los Angeles, CA 90013
6 Telephone: (213) 269-6481
Facsimile: (916) 731-2117
7 *Attorneys for Complainant*

8
9 **BEFORE THE**
10 **MEDICAL BOARD OF CALIFORNIA**
11 **DEPARTMENT OF CONSUMER AFFAIRS**
12 **STATE OF CALIFORNIA**

13 In the Matter of the Accusation Against:
14 **EMIL SOORANI, M.D.**
15 **P.O. Box 1107**
16 **Topanga, California 90290**
17 **Physician's and Surgeon's Certificate No.**
18 **A37184,**
19 Respondent.

Case Nos. 800-2015-011341; 800-2019-
055308; 800-2020-067224

OAH No. 2021010789

**STIPULATED SETTLEMENT AND
DISCIPLINARY ORDER**

20 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-
entitled proceedings that the following matters are true:

21 **PARTIES**

- 22 1. William Prasifka (Complainant) is the Executive Director of the Medical Board of
23 California (Board). He brought this action solely in his official capacity and is represented in this
24 matter by Rob Bonta, Attorney General of the State of California, by Christina Sein Goot, Deputy
25 Attorney General.
- 26 2. Respondent Emil Soorani, M.D. (Respondent) is represented in this proceeding by
27 attorney Joel Bruce Douglas, whose address is: 355 South Grand Ave., Ste. 1750, Los Angeles,
28 CA 90071-1562.

1 CULPABILITY

2 10. Respondent understands and agrees that the charges and allegations in Accusation
3 No. 800-2015-011341, if proven at a hearing, constitute cause for imposing discipline upon his
4 Physician's and Surgeon's Certificate.

5 11. Respondent does not contest that, at an administrative hearing, Complainant could
6 establish a *prima facie* case with respect to the charges and allegations contained in Accusation
7 No. 800-2015-011341, that he has thereby subjected his license to disciplinary action and hereby
8 gives up his right to contest those charges.

9 12. Respondent agrees that his Physician's and Surgeon's Certificate is subject to
10 discipline and he agrees to be bound by the Board's probationary terms as set forth in the
11 Disciplinary Order below.

12 CONTINGENCY

13 13. This stipulation shall be subject to approval by the Medical Board of California.
14 Respondent understands and agrees that counsel for Complainant and the staff of the Medical
15 Board of California may communicate directly with the Board regarding this stipulation and
16 settlement, without notice to or participation by Respondent or his counsel. By signing the
17 stipulation, Respondent understands and agrees that he may not withdraw his agreement or seek
18 to rescind the stipulation prior to the time the Board considers and acts upon it. If the Board fails
19 to adopt this stipulation as its Decision and Order, the Stipulated Settlement and Disciplinary
20 Order shall be of no force or effect, except for this paragraph, it shall be inadmissible in any legal
21 action between the parties, and the Board shall not be disqualified from further action by having
22 considered this matter.

23 14. Respondent agrees that if he ever petitions for early termination or modification of
24 probation, or if an accusation and/or petition to revoke probation is filed against him before the
25 Board, all of the charges and allegations contained in Accusation No. 800-2015-011341 shall be
26 deemed true, correct and fully admitted by respondent for purposes of any such proceeding or any
27 other licensing proceeding involving Respondent in the State of California.

28 15. The parties understand and agree that Portable Document Format (PDF) and facsimile

1 copies of this Stipulated Settlement and Disciplinary Order, including PDF and facsimile
2 signatures thereto, shall have the same force and effect as the originals.

3 16. In consideration of the foregoing admissions and stipulations, the parties agree that
4 the Board may, without further notice or opportunity to be heard by the Respondent, issue and
5 enter the following Disciplinary Order:

6 **DISCIPLINARY ORDER**

7 IT IS HEREBY ORDERED that Physician's and Surgeon's Certificate No. A 37184 issued
8 to Respondent EMIL SOORANI, M.D. is revoked. However, the revocation is stayed and
9 Respondent is placed on probation for five (5) years on the following terms and conditions:

10 1. **CONTROLLED SUBSTANCES - PARTIAL RESTRICTION.** Respondent shall not
11 order, prescribe, dispense, administer, furnish, or possess the following controlled substances, as
12 defined by the California Uniform Controlled Substances Act: Schedule II controlled substances
13 identified in California Health and Safety Code section 11055, subdivisions (b), (c), (e), and (f).

14 Respondent shall not issue an oral or written recommendation or approval to a patient or a
15 patient's primary caregiver for the possession or cultivation of marijuana for the personal medical
16 purposes of the patient within the meaning of Health and Safety Code section 11362.5. If
17 Respondent forms the medical opinion, after an appropriate prior examination and medical
18 indication, that a patient's medical condition may benefit from the use of marijuana, Respondent
19 shall so inform the patient and shall refer the patient to another physician who, following an
20 appropriate prior examination and medical indication, may independently issue a medically
21 appropriate recommendation or approval for the possession or cultivation of marijuana for the
22 personal medical purposes of the patient within the meaning of Health and Safety Code section
23 11362.5. In addition, Respondent shall inform the patient or the patient's primary caregiver that
24 Respondent is prohibited from issuing a recommendation or approval for the possession or
25 cultivation of marijuana for the personal medical purposes of the patient and that the patient or
26 the patient's primary caregiver may not rely on Respondent's statements to legally possess or
27 cultivate marijuana for the personal medical purposes of the patient. Respondent shall fully
28 document in the patient's chart that the patient or the patient's primary caregiver was so

1 informed. Nothing in this condition prohibits Respondent from providing the patient or the
2 patient's primary caregiver information about the possible medical benefits resulting from the use
3 of marijuana.

4 2. CONTROLLED SUBSTANCES - MAINTAIN RECORDS AND ACCESS TO
5 RECORDS AND INVENTORIES. Respondent shall maintain a record of all controlled
6 substances ordered, prescribed, dispensed, administered, or possessed by Respondent, and any
7 recommendation or approval which enables a patient or patient's primary caregiver to possess or
8 cultivate marijuana for the personal medical purposes of the patient within the meaning of Health
9 and Safety Code section 11362.5, during probation, showing all of the following: 1) the initials
10 and date of birth of the patient; 2) the date; 3) the character and quantity of controlled substances
11 involved; and 4) the indications and diagnosis for which the controlled substances were furnished.

12 Respondent shall keep these records in a separate file or ledger, in chronological order. All
13 records and any inventories of controlled substances shall be available for immediate inspection
14 and copying on the premises by the Board or its designee at all times during business hours and
15 shall be retained for the entire term of probation.

16 3. EDUCATION COURSE. Within 60 calendar days of the effective date of this
17 Decision, and on an annual basis thereafter, Respondent shall submit to the Board or its designee
18 for its prior approval educational program(s) or course(s) which shall not be less than 20 hours
19 per year, for each year of probation. The educational program(s) or course(s) shall be aimed at
20 correcting any areas of deficient practice or knowledge and shall be Category I certified. The
21 educational program(s) or course(s) shall be at Respondent's expense and shall be in addition to
22 the Continuing Medical Education (CME) requirements for renewal of licensure. Following the
23 completion of each course, the Board or its designee may administer an examination to test
24 Respondent's knowledge of the course. Respondent shall provide proof of attendance for 45
25 hours of CME of which 20 hours were in satisfaction of this condition.

26 4. PRESCRIBING PRACTICES COURSE. Within 60 calendar days of the effective
27 date of this Decision, Respondent shall enroll in a course in prescribing practices approved in
28 advance by the Board or its designee. Respondent shall provide the approved course provider

1 with any information and documents that the approved course provider may deem pertinent.
2 Respondent shall participate in and successfully complete the classroom component of the course
3 not later than six (6) months after Respondent's initial enrollment. Respondent shall successfully
4 complete any other component of the course within one (1) year of enrollment. The prescribing
5 practices course shall be at Respondent's expense and shall be in addition to the Continuing
6 Medical Education (CME) requirements for renewal of licensure.

7 A prescribing practices course taken after the acts that gave rise to the charges in the
8 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board
9 or its designee, be accepted towards the fulfillment of this condition if the course would have
10 been approved by the Board or its designee had the course been taken after the effective date of
11 this Decision.

12 Respondent shall submit a certification of successful completion to the Board or its
13 designee not later than 15 calendar days after successfully completing the course, or not later than
14 15 calendar days after the effective date of the Decision, whichever is later.

15 5. MEDICAL RECORD KEEPING COURSE. Within 60 calendar days of the effective
16 date of this Decision, Respondent shall enroll in a course in medical record keeping approved in
17 advance by the Board or its designee. Respondent shall provide the approved course provider
18 with any information and documents that the approved course provider may deem pertinent.
19 Respondent shall participate in and successfully complete the classroom component of the course
20 not later than six (6) months after Respondent's initial enrollment. Respondent shall successfully
21 complete any other component of the course within one (1) year of enrollment. The medical
22 record keeping course shall be at Respondent's expense and shall be in addition to the Continuing
23 Medical Education (CME) requirements for renewal of licensure.

24 A medical record keeping course taken after the acts that gave rise to the charges in the
25 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board
26 or its designee, be accepted towards the fulfillment of this condition if the course would have
27 been approved by the Board or its designee had the course been taken after the effective date of
28 this Decision.

1 Respondent shall submit a certification of successful completion to the Board or its
2 designee not later than 15 calendar days after successfully completing the course, or not later than
3 15 calendar days after the effective date of the Decision, whichever is later.

4 6. MONITORING - PRACTICE. Within 30 calendar days of the effective date of this
5 Decision, Respondent shall submit to the Board or its designee for prior approval as a practice
6 monitor, the name and qualifications of one or more licensed physicians and surgeons whose
7 licenses are valid and in good standing, and who are preferably American Board of Medical
8 Specialties (ABMS) certified. A monitor shall have no prior or current business or personal
9 relationship with Respondent, or other relationship that could reasonably be expected to
10 compromise the ability of the monitor to render fair and unbiased reports to the Board, including
11 but not limited to any form of bartering, shall be in Respondent's field of practice, and must agree
12 to serve as Respondent's monitor. Respondent shall pay all monitoring costs.

13 The Board or its designee shall provide the approved monitor with copies of the Decision(s)
14 and Accusation(s), and a proposed monitoring plan. Within 15 calendar days of receipt of the
15 Decision(s), Accusation(s), and proposed monitoring plan, the monitor shall submit a signed
16 statement that the monitor has read the Decision(s) and Accusation(s), fully understands the role
17 of a monitor, and agrees or disagrees with the proposed monitoring plan. If the monitor disagrees
18 with the proposed monitoring plan, the monitor shall submit a revised monitoring plan with the
19 signed statement for approval by the Board or its designee.

20 Within 60 calendar days of the effective date of this Decision, and continuing throughout
21 probation, Respondent's entire practice shall be monitored by the approved monitor. Respondent
22 shall make all records available for immediate inspection and copying on the premises by the
23 monitor at all times during business hours and shall retain the records for the entire term of
24 probation.

25 If Respondent fails to obtain approval of a monitor within 60 calendar days of the effective
26 date of this Decision, Respondent shall receive a notification from the Board or its designee to
27 cease the practice of medicine within three (3) calendar days after being so notified. Respondent
28 shall cease the practice of medicine until a monitor is approved to provide monitoring

1 responsibility.

2 The monitor(s) shall submit a quarterly written report to the Board or its designee which
3 includes an evaluation of Respondent's performance, indicating whether Respondent's practices
4 are within the standards of practice of medicine, and whether Respondent is practicing medicine
5 safely. It shall be the sole responsibility of Respondent to ensure that the monitor submits the
6 quarterly written reports to the Board or its designee within 10 calendar days after the end of the
7 preceding quarter.

8 If the monitor resigns or is no longer available, Respondent shall, within 5 calendar days of
9 such resignation or unavailability, submit to the Board or its designee, for prior approval, the
10 name and qualifications of a replacement monitor who will be assuming that responsibility within
11 15 calendar days. If Respondent fails to obtain approval of a replacement monitor within 60
12 calendar days of the resignation or unavailability of the monitor, Respondent shall receive a
13 notification from the Board or its designee to cease the practice of medicine within three (3)
14 calendar days after being so notified. Respondent shall cease the practice of medicine until a
15 replacement monitor is approved and assumes monitoring responsibility.

16 In lieu of a monitor, Respondent may participate in a professional enhancement program
17 approved in advance by the Board or its designee that includes, at minimum, quarterly chart
18 review, semi-annual practice assessment, and semi-annual review of professional growth and
19 education. Respondent shall participate in the professional enhancement program at Respondent's
20 expense during the term of probation.

21 7. NOTIFICATION. Within seven (7) days of the effective date of this Decision, the
22 Respondent shall provide a true copy of this Decision and Accusation to the Chief of Staff or the
23 Chief Executive Officer at every hospital where privileges or membership are extended to
24 Respondent, at any other facility where Respondent engages in the practice of medicine,
25 including all physician and locum tenens registries or other similar agencies, and to the Chief
26 Executive Officer at every insurance carrier which extends malpractice insurance coverage to
27 Respondent. Respondent shall submit proof of compliance to the Board or its designee within 15
28 calendar days.

1 This condition shall apply to any change(s) in hospitals, other facilities or insurance carrier.

2 8. SUPERVISION OF PHYSICIAN ASSISTANTS AND ADVANCED PRACTICE
3 NURSES. During probation, Respondent is prohibited from supervising physician assistants and
4 advanced practice nurses.

5 9. OBEY ALL LAWS. Respondent shall obey all federal, state and local laws, all rules
6 governing the practice of medicine in California and remain in full compliance with any court
7 ordered criminal probation, payments, and other orders.

8 10. QUARTERLY DECLARATIONS. Respondent shall submit quarterly declarations
9 under penalty of perjury on forms provided by the Board, stating whether there has been
10 compliance with all the conditions of probation.

11 Respondent shall submit quarterly declarations not later than 10 calendar days after the end
12 of the preceding quarter.

13 11. GENERAL PROBATION REQUIREMENTS.

14 Compliance with Probation Unit

15 Respondent shall comply with the Board's probation unit.

16 Address Changes

17 Respondent shall, at all times, keep the Board informed of Respondent's business and
18 residence addresses, email address (if available), and telephone number. Changes of such
19 addresses shall be immediately communicated in writing to the Board or its designee. Under no
20 circumstances shall a post office box serve as an address of record, except as allowed by Business
21 and Professions Code section 2021, subdivision (b).

22 Place of Practice

23 Respondent shall not engage in the practice of medicine in Respondent's or patient's place
24 of residence, unless the patient resides in a skilled nursing facility or other similar licensed
25 facility.

26 License Renewal

27 Respondent shall maintain a current and renewed California physician's and surgeon's
28 license.

1 Travel or Residence Outside California

2 Respondent shall immediately inform the Board or its designee, in writing, of travel to any
3 areas outside the jurisdiction of California which lasts, or is contemplated to last, more than thirty
4 (30) calendar days.

5 In the event Respondent should leave the State of California to reside or to practice
6 ,Respondent shall notify the Board or its designee in writing 30 calendar days prior to the dates of
7 departure and return.

8 12. INTERVIEW WITH THE BOARD OR ITS DESIGNEE. Respondent shall be
9 available in person upon request for interviews either at Respondent's place of business or at the
10 probation unit office, with or without prior notice throughout the term of probation.

11 13. NON-PRACTICE WHILE ON PROBATION. Respondent shall notify the Board or
12 its designee in writing within 15 calendar days of any periods of non-practice lasting more than
13 30 calendar days and within 15 calendar days of Respondent's return to practice. Non-practice is
14 defined as any period of time Respondent is not practicing medicine as defined in Business and
15 Professions Code sections 2051 and 2052 for at least 40 hours in a calendar month in direct
16 patient care, clinical activity or teaching, or other activity as approved by the Board. If
17 Respondent resides in California and is considered to be in non-practice, Respondent shall
18 comply with all terms and conditions of probation. All time spent in an intensive training
19 program which has been approved by the Board or its designee shall not be considered non-
20 practice and does not relieve Respondent from complying with all the terms and conditions of
21 probation. Practicing medicine in another state of the United States or Federal jurisdiction while
22 on probation with the medical licensing authority of that state or jurisdiction shall not be
23 considered non-practice. A Board-ordered suspension of practice shall not be considered as a
24 period of non-practice.

25 In the event Respondent's period of non-practice while on probation exceeds 18 calendar
26 months, Respondent shall successfully complete the Federation of State Medical Boards's Special
27 Purpose Examination, or, at the Board's discretion, a clinical competence assessment program
28 that meets the criteria of Condition 18 of the current version of the Board's "Manual of Model

1 Disciplinary Orders and Disciplinary Guidelines” prior to resuming the practice of medicine.

2 Respondent’s period of non-practice while on probation shall not exceed two (2) years.

3 Periods of non-practice will not apply to the reduction of the probationary term.

4 Periods of non-practice for a Respondent residing outside of California will relieve
5 Respondent of the responsibility to comply with the probationary terms and conditions with the
6 exception of this condition and the following terms and conditions of probation: Obey All Laws;
7 General Probation Requirements; Quarterly Declarations; Abstain from the Use of Alcohol and/or
8 Controlled Substances; and Biological Fluid Testing..

9 14. COMPLETION OF PROBATION. Respondent shall comply with all financial
10 obligations (e.g., restitution, probation costs) not later than 120 calendar days prior to the
11 completion of probation. Upon successful completion of probation, Respondent’s certificate shall
12 be fully restored.

13 15. VIOLATION OF PROBATION. Failure to fully comply with any term or condition
14 of probation is a violation of probation. If Respondent violates probation in any respect, the
15 Board, after giving Respondent notice and the opportunity to be heard, may revoke probation and
16 carry out the disciplinary order that was stayed. If an Accusation, or Petition to Revoke Probation,
17 or an Interim Suspension Order is filed against Respondent during probation, the Board shall have
18 continuing jurisdiction until the matter is final, and the period of probation shall be extended until
19 the matter is final.

20 16. LICENSE SURRENDER. Following the effective date of this Decision, if
21 Respondent ceases practicing due to retirement or health reasons or is otherwise unable to satisfy
22 the terms and conditions of probation, Respondent may request to surrender his or her license.
23 The Board reserves the right to evaluate Respondent’s request and to exercise its discretion in
24 determining whether or not to grant the request, or to take any other action deemed appropriate
25 and reasonable under the circumstances. Upon formal acceptance of the surrender, Respondent
26 shall within 15 calendar days deliver Respondent’s wallet and wall certificate to the Board or its
27 designee and Respondent shall no longer practice medicine. Respondent will no longer be subject
28 to the terms and conditions of probation. If Respondent re-applies for a medical license, the

1 application shall be treated as a petition for reinstatement of a revoked certificate.

2 17. PROBATION MONITORING COSTS. Respondent shall pay the costs associated
3 with probation monitoring each and every year of probation, as designated by the Board, which
4 may be adjusted on an annual basis. Such costs shall be payable to the Medical Board of
5 California and delivered to the Board or its designee no later than January 31 of each calendar
6 year.

7 18. FUTURE ADMISSIONS CLAUSE. If Respondent should ever apply or reapply for
8 a new license or certification, or petition for reinstatement of a license, by any other health care
9 licensing action agency in the State of California, all of the charges and allegations contained in
10 Accusation No. 800-2015-011341 shall be deemed to be true, correct, and admitted by
11 Respondent for the purpose of any Statement of Issues or any other proceeding seeking to deny or
12 restrict license.

13 ACCEPTANCE

14 I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully
15 discussed it with my attorney, Joel Bruce Douglas. I understand the stipulation and the effect it
16 will have on my Physician's and Surgeon's Certificate. I enter into this Stipulated Settlement and
17 Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the
18 Decision and Order of the Medical Board of California.

19
20 DATED: Sept 21, 2021



EMIL SOORANI, M.D.
Respondent

21
22
23 I have read and fully discussed with Respondent Emil Soorani, M.D. the terms and
24 conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order.
25 I approve its form and content.

26
27 DATED: Sept. 21, 2021



JOEL BRUCE DOUGLAS, ESQ.
Attorney for Respondent

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28


ENDORSEMENT

The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully submitted for consideration by the Medical Board of California.

DATED: 9/22/21

Respectfully submitted,

ROB BONTA
Attorney General of California
ROBERT MCKIM BELL
Supervising Deputy Attorney General



CHRISTINA SEIN GOOT
Deputy Attorney General
Attorneys for Complainant

LA2020501050
64544507.docx

Exhibit A

Accusation No. 800-2015-011341

1 XAVIER BECERRA
Attorney General of California
2 E. A. JONES III
Supervising Deputy Attorney General
3 JOSHUA M. TEMPLET
Deputy Attorney General
4 State Bar No. 267098
California Department of Justice
5 300 So. Spring Street, Suite 1702
Los Angeles, CA 90013
6 Telephone: (213) 269-6688
Facsimile: (916) 731-2311
7 E-mail: Joshua.Templet@doj.ca.gov
Attorneys for Complainant
8

9
10 **BEFORE THE**
MEDICAL BOARD OF CALIFORNIA
DEPARTMENT OF CONSUMER AFFAIRS
11 **STATE OF CALIFORNIA**
12

13 In the Matter of the Accusation Against:

Case No. 800-2015-011341

14 **Emil Soorani, M.D.**
15 **P.O. Box 1107**
Topanga, CA 90290

ACCUSATION

16 **Physician's and Surgeon's Certificate**
17 **No. A 37184,**

18 Respondent.
19

20
21 **PARTIES**

22 1. Christine J. Lally (Complainant) brings this Accusation solely in her official capacity
23 as the Interim Executive Director of the Medical Board of California, Department of Consumer
24 Affairs (Board).

25 2. On July 27, 1981, the Board issued Physician's and Surgeon's Certificate Number
26 A 37184 to Emil Soorani, M.D. (Respondent). The certificate was in full force and effect at all
27 times relevant to the charges brought herein and will expire on July 31, 2021, unless renewed.

28 ///

1 **JURISDICTION**

2 3. This Accusation is brought before the Board, under the authority of the following
3 laws. All section references are to the Business and Professions Code (Code) unless otherwise
4 indicated.

5 4. Section 2004 provides that the Board shall have the responsibility for the enforcement
6 of the disciplinary and criminal provisions of the Medical Practice Act.

7 5. Section 2227 authorizes the Board to take action against a licensee who has been
8 found guilty under the Medical Practice Act by revoking his or her license, suspending the license
9 for a period not to exceed one year, placing the license on probation and requiring payment of
10 costs of probation monitoring, or taking such other action as the Board deems proper.

11 6. At all times relevant to this matter, Respondent was licensed and practicing medicine
12 in California.

13 **STATUTORY PROVISIONS**

14 7. Section 2234 states:

15 The board shall take action against any licensee who is charged with unprofessional
16 conduct. In addition to other provisions of this article, unprofessional conduct
includes, but is not limited to, the following:

17 (a) Violating or attempting to violate, directly or indirectly, assisting in or abetting the
18 violation of, or conspiring to violate any provision of this chapter.

19 (b) Gross negligence.

20 (c) Repeated negligent acts. To be repeated, there must be two or more negligent acts
21 or omissions. An initial negligent act or omission followed by a separate and distinct
departure from the applicable standard of care shall constitute repeated negligent acts.

22 (1) An initial negligent diagnosis followed by an act or omission medically
23 appropriate for that negligent diagnosis of the patient shall constitute a single
negligent act.

24 (2) When the standard of care requires a change in the diagnosis, act, or omission that
25 constitutes the negligent act described in paragraph (1), including, but not limited to,
26 a reevaluation of the diagnosis or a change in treatment, and the licensee's conduct
27 departs from the applicable standard of care, each departure constitutes a separate and
distinct breach of the standard of care.

28 (d) Incompetence.

1 in remission, and she no longer needed an antidepressant. At that time, she remained on a
2 medication for anxiety and stress. Respondent also noted that the patient had been sober from
3 alcohol for a long time, suggesting a history of alcohol abuse.

4 13. A legible note in the patient's records, dated August 29, 2013, indicates that
5 Respondent was notified that another provider was prescribing the patient Ambien, and that the
6 patient had sought an early refill of her medication. A few months later, Respondent began
7 prescribing the patient Ambien while she was also receiving it from the other provider. The
8 patient filled prescriptions for Ambien by the other provider on December 11, 2013 and January
9 27, 2014. She also filled Ambien prescriptions from Respondent on January 3, 2014, February 5,
10 2014, and March 5, 2014.

11 14. Respondent resumed prescribing the patient Ambien, in February 2016, and by May
12 2016 the patient was again obtaining early refills of her medication. The patient's early refills of
13 her medications and her seeking simultaneous prescriptions from more than one provider
14 indicated that she was taking more medication than directed, a sign that she may have developed
15 tolerance to and withdrawal from the medication and that she had become addicted to it. Ambien
16 is addictive, particularly to an individual who is predisposed to addiction, as this patient appears
17 to have been, given her history of alcohol abuse. In addition, Ambien is a sedative that can
18 synergistically interact with the many opiates that Respondent was also prescribing this patient,
19 resulting in a potentially dangerous combined sedative effect on the patient.

20 15. Respondent's failure to maintain adequate records of his treatment of P-1 was a
21 departure from the standard of care. His progress notes are illegible, and his summary-of-care
22 letters do not provide an accurate and complete account of his treatment.

23 16. Respondent's diagnosis of the patient with "Pain Disorder," without documenting any
24 evaluation of the patient's pain and without specifying whether its etiology was psychological,
25 physical, or both, was a departure from the standard of care.

26 ///

27 _____
28 is a Schedule IV controlled substance under Health and Safety Code section 11057, subdivision
(d)(7), and a dangerous drug as defined in Business and Professions Code section 4022.

1 17. Respondent's continued prescribing of Ambien to this patient despite warning signs
2 of her addiction to it, and his failure to document taking steps to address her potential addiction or
3 to justify his continued prescribing was a departure from the standard of care.

4 **Patient P-2**

5 18. Respondent treated P-2 from approximately January 8, 2005, through at least
6 September 2, 2016. Respondent's records of his treatment of P-2 consist of handwritten progress
7 notes, which are illegible apart from the dates of the notes. Among the records are two typed
8 letters by Respondent dated September 14, 2012, and July 10, 2014, summarizing his care of the
9 patient. According to his letters, Respondent had been treating P-2 for Major Depressive
10 Disorder, not otherwise specified, and Anxiety Disorder, not otherwise specified. Both letters
11 conclude that the patient remained totally disabled from all occupational functioning. The July 10,
12 2014, letter states that his disability was in part physical due to "severe injury to right arm with
13 permanent nerve damage."

14 19. The July 10, 2014, letter notes some improvement in the patient's Major Depressive
15 Disorder. The letter does not document any pharmacological treatment for the patient's Major
16 Depressive Disorder, such as an antidepressant medication. The letter notes that Respondent
17 prescribed the patient Ambien, but Respondent did not document any basis for this medication,
18 such as the patient's diagnosis with a sleep disorder.

19 20. The treatment that Respondent documented in his summary-of-care letters conflicts
20 with Controlled Substance Utilization Review and Evaluation System (CURES)⁵ reports of his
21 prescribing. Respondent's July 10, 2014, letter states that Respondent prescribed the patient two
22 10 mg tablets of dextroamphetamine⁶ in the morning and one to two tablets in the evening, "for
23 focus." CURES reports, however, show that Respondent prescribed the patient a higher daily
24 dose of dextroamphetamine, and that the dose and timing of the prescriptions fluctuated.

25 ⁵ The Controlled Substance Utilization Review and Evaluation System (CURES) is a
26 database of Schedule II, III, and IV controlled substance prescriptions dispensed in California,
27 serving regulatory oversight agencies, law enforcement, public health, and health care providers.

28 ⁶ Dextroamphetamine (Dexedrine®) is a stimulant used to treat ADHD and narcolepsy. It
is a Schedule II controlled substance under Health and Safety Code section 11055, subdivision
(d)(1), and a dangerous drug as defined in Business and Professions Code section 4022.

1 Respondent did not document an explanation for these fluctuations. There were also times when
2 P-2 filled his prescription for dextroamphetamine early. Respondent did not document his
3 acknowledgment or an explanation of this. In addition, although Respondent states in his letters
4 that he prescribed the patient 1 mg of Klonopin⁷ as needed for anxiety, CURES reports show that
5 in fact he prescribed the patient a 4 mg daily dose of Klonopin, a much higher dose, at a level that
6 causes tolerance and withdrawal.

7 21. Respondent treated the patient with an aggressive and risky combination of
8 psychiatric medications, including Abilify, an antipsychotic medication; dextroamphetamine for
9 attention deficit hyperactivity disorder (ADHD); Klonopin for anxiety; Ambien for unknown
10 reasons; and Synthroid, which is used to augment the antidepressant effects of antidepressant
11 medications. Such a large number of psychiatric medications taken concurrently poses the risk of
12 detrimental interactions between the drugs. In addition, three of the medications are addictive:
13 dextroamphetamine, Klonopin, and Ambien. Respondent did not justify the risks of these
14 medications, given the patient's lack of improvement from being totally disabled from all
15 occupational functioning. In addition, while Respondent diagnosed the patient with Major
16 Depressive Disorder, according to his July 10, 2014, summary-of-care letter, Respondent did not
17 treat him with an antidepressant medication.

18 22. Respondent's failure to maintain adequate records of his treatment of P-2 was an
19 extreme departure from the standard of care. His progress notes are illegible, and his summary-of-
20 care letters do not provide an accurate and complete account of his treatment.

21 23. Respondent's failure to justify the risks of the medication regimen he prescribed to
22 P-2, given the patient's lack of response to the medication, and his cessation of prescribing an
23 antidepressant medication for the patient's Major Depressive Disorder was a departure from the
24 standard of care.

25 ///

26 ///

27 ///

28 ⁷ Klonopin® is a brand name of clonazepam, described above, at footnote 4.

1 **Patient P-3**

2 24. Respondent treated P-3 from approximately February 2, 2012, through January 2,
3 2016. Respondent's records of his treatment of P-3 consist of handwritten progress notes, which
4 are illegible apart from the dates of the notes. Also among the records are some typewritten
5 documents and psychological tests, which are legible.

6 25. The February 2, 2012, initial evaluation form completed by Respondent includes
7 check marks next to "Pain Disorder," and "296.22," which is a DSM-IV-TR code for Major
8 Depressive Disorder, Single Episode, Moderate. While legible portions of the records, including
9 the patient's complaints and the findings of a mental status examination by Respondent, support
10 the presumed diagnosis of Major Depressive Disorder, there is no basis to support the presumed
11 diagnosis of "Pain Disorder."

12 26. CURES reports show that Respondent prescribed the patient Ambien and Klonopin
13 for years, over the course of his treatment of the patient. Respondent continued to prescribe these
14 medications to the patient through April 2016, months after the date of the last record of his
15 treatment of the patient, on January 2, 2016.

16 27. Respondent prescribed the patient excessive amounts of Ambien, by simultaneously
17 prescribing him two different formulations of the medication (immediate release and controlled
18 release), each at the highest daily dose. The patient in turn was regularly obtaining early refills of
19 these prescriptions. The patient's early refills indicated that he was taking more medication than
20 directed, a sign that he may have developed tolerance to and withdrawal from the medication and
21 that he had become addicted to it.

22 28. Respondent's failure to maintain adequate records of his treatment of P-3 was an
23 extreme departure from the standard of care. His progress notes are illegible, the records do not
24 provide an accurate and complete account of his treatment, and there are no records supporting
25 the final months of his prescribing of controlled substances to this patient.

26 29. Respondent's diagnosis of the patient with "Pain Disorder," without documenting any
27 evaluation of the patient's pain and without specifying whether its etiology was psychological,
28 physical, or both, was a departure from the standard of care.

1 30. Respondent's prescribing of excessive amounts of Ambien to this patient despite
2 warning signs of his addiction to it, and his failure to document taking steps to address his
3 potential addiction and to justify his continued prescribing was a departure from the standard of
4 care.

5 **Patient P-4**

6 31. Respondent treated P-4 from approximately April 19, 2013, through July 21, 2016.
7 Respondent's records of his treatment of P-4 consist of handwritten progress notes, most of which
8 are illegible apart from the dates of the notes. There appear to be different authors of records
9 throughout the chart, based on varying legibility of the handwritten records. Also, among the
10 records are some typewritten documents, which are legible, including a letter from Respondent
11 dated January 3, 2014, summarizing care of the patient. According to his letter, Respondent had
12 been treating P-4 for "pain management purposes, secondary to a diagnosis of Severe Chronic
13 Pain."

14 32. According to pharmacy records obtained by the Board, Respondent prescribed the
15 patient a number of psychiatric medications over the course of his treatment. He also prescribed
16 the patient opiates, such as fentanyl⁸ and oxycodone.⁹

17 33. Respondent's failure to maintain adequate records of his treatment of P-4 was an
18 extreme departure from the standard of care. His progress notes are illegible, the records do not
19 provide an accurate and complete account of his treatment, and it is impossible to determine for
20 which psychiatric conditions Respondent treated the patient.

21 ///

22 ///

23 ///

24 ///

25 _____
26 ⁸ Fentanyl is a Schedule II controlled substance under Health and Safety Code section
27 11055, subdivision (c)(8), and a dangerous drug as defined in Business and Professions Code
28 section 4022.

⁹ Oxycodone is a Schedule II controlled substance under Health and Safety Code section
11055, subdivision (b)(1)(M), and a dangerous drug as defined in Business and Professions Code
section 4022.

1 **Patient P-5**

2 34. Respondent treated P-5 from approximately May 8, 2012, through March 18, 2016.
3 Respondent's records of his treatment of P-5 consist of handwritten progress notes, most of which
4 are illegible apart from the dates of the notes, and copies of prescriptions. Also, among the
5 records are some typewritten documents, including several letters from Respondent summarizing
6 care of the patient.

7 35. During his initial evaluation, the patient completed a Beck Depression Inventory and
8 a Beck Anxiety Inventory, scoring zero on each, which is within normal limits. P-5 also
9 completed an Adult ADHD Self-Report Scale. The patient scored 22 on this—scores of 11 points
10 or higher indicate symptoms that may be consistent with adult ADHD. The patient noted no
11 psychiatric complaints in his initial evaluation paperwork.

12 36. Respondent diagnosed P-5 with ADHD based on his first visit, when he was 39 years
13 old. The only basis for this diagnosis appears to be the Adult ADHD Self-Report Scale, which is
14 an insufficient basis to diagnose ADHD. There is no documentation that the patient was suffering
15 from active ADHD, that he had had a clinical course indicative of the condition, or that he had
16 been previously diagnosed with ADHD. This is not indicative of an individual who suffers from
17 ADHD in adulthood, as the condition first emerges in childhood (and in most patients resolves by
18 adulthood).

19 37. In August 2013, the patient injured his knee in a skiing accident, after which
20 Respondent treated him for pain, including by prescribing him opiates like oxycodone and
21 fentanyl.

22 38. In December 2012, six months after the patient's first visit, pharmacy records
23 obtained by the Board show that Respondent began prescribing P-5 a high dose of Klonopin,
24 which Respondent later confirmed was used to treat the patient's anxiety. But just a few months
25 earlier, at his initial evaluation, the patient had no complaints of anxiety, and he had a negative
26 inventory for anxiety. Respondent did not explain the origin of the patient's apparent

27 ///

28 ///

1 new anxiety. One explanation that Respondent should have considered was that the high doses of
2 stimulants that Respondent had begun prescribing the patient after his first visit were causing the
3 patient to exhibit symptoms consistent with anxiety.

4 39. Respondent also diagnosed the patient with excessive daytime sleepiness, but
5 Respondent's records do not document any consideration that the patient was simply sedated
6 from the high-dose opiates and Klonopin that Respondent prescribed him. Nor did Respondent
7 explain the origin of his diagnoses of the patient with depression or PTSD.

8 40. During the course of his treatment of P-5, Respondent prescribed him excessive
9 amounts of addictive stimulants. For example, Respondent prescribed P-5 Vyvanse¹⁰ at the FDA
10 maximum dose of 70 mg daily, concurrently with a high dose of Dexedrine¹¹ 10 mg two tablets
11 three times a day, for a daily dose of 60 mg. While prescribing this aggressive treatment for
12 ADHD, Respondent was giving the patient an additional stimulant—Nuvigil¹² 250 mg in the
13 morning. When combined with the two other stimulant medications, Nuvigil can have a
14 synergistic effect that could cause increased anxiety and insomnia, and even lead to psychosis in
15 some patients. Moreover, this was coupled with the stimulating antidepressant Wellbutrin¹³ at a
16 high dose of 450 mg in the morning. This exceeds the typical dose, but it is not uncommon by
17 itself. However, in the context of the three other stimulant medications, this amount of Wellbutrin
18 was extremely aggressive, could have been dangerous, and almost surely provoked anxiety in the
19 patient.

20 ///

21 ///

22 ///

23
24 ¹⁰ Lisdexamfetamine (Vyvanse®) is a stimulant used to treat ADHD. It is a Schedule II
25 controlled substance as defined by section 1308.12, subdivision (d)(5), of Title 21 of the Code of
26 Federal Regulations and a dangerous drug as defined in Business and Professions Code section
27 4022.

28 ¹¹ Dexedrine® is a brand name of dextroamphetamine, described above, at footnote 6.

¹² Armodafinil (Nuvigil®) is a stimulant used to treat narcolepsy. It is a Schedule IV
controlled substance under Health and Safety Code section 11057, subdivision (f), and a
dangerous drug as defined in Business and Professions Code section 4022.

¹³ Bupropion (Wellbutrin®) is an antidepressant used to treat depression. It is a dangerous
drug as defined in Code section 4022.

1 41. According to Respondent's summary-of-care letters, by 2016, he was prescribing the
2 patient some 17 medications. The patient's condition does not appear to have improved as a result
3 of Respondent's treatment, as Respondent continued to report through 2016 that the patient
4 remained totally disabled and was unable to work fulltime.

5 42. After his last visit with Respondent, on or about May 18, 2016, P-5 sought treatment
6 from a pain management physician and then entered a rehabilitation facility, where he was
7 weaned off of opiate medications.

8 43. Respondent's failure to maintain adequate records of his treatment of P-5 was a
9 departure from the standard of care. His progress notes are illegible, and his summary-of-care
10 letters do not provide a complete account of his treatment, including the basis for his assessment
11 and the reasoning supporting his treatment.

12 44. Respondent's unsupported diagnoses of the patient with ADHD, anxiety, depression,
13 PTSD and excessive daytime sleepiness and his failure to consider whether his prescribed
14 medication regimen, numbering some 17 medications at one point, was causing the symptoms
15 underlying these diagnoses was an extreme departure from the standard of care.

16 45. Respondent's failure to justify the risks of the medication regimen he prescribed to
17 P-5, which included excessive amounts of addictive stimulants, given the patient's lack of
18 response to the medication, was an extreme departure from the standard of care.

19 **Patient P-6**

20 46. Respondent treated P-6 from approximately November 1, 2012, when she was 40
21 years old, through March 23, 2016. Respondent's records of his treatment of P-6 consist of
22 handwritten progress notes, most of which are illegible apart from the dates of the notes, and
23 copies of prescriptions and correspondence with health insurance companies.

24 47. A March 25, 2014, disability insurance form and related letter from Respondent
25 indicates that Respondent diagnosed the patient with Bipolar Disorder, Severe, Depressed with
26 Psychotic Features; ADHD; and Pain Disorder of neck, feet, and wrist. The letter continues,
27 "Patient continues to exhibit morbid depression, impulse behavior and delusional thinking. She is
28 currently on several psychotropic medications and sees me regularly."

1 48. There is no legible documentation of any test results, history, or current
2 symptomatology to support the patient's diagnosis with ADHD. Also, P-6 completed a patient
3 questionnaire at the start of her treatment, in which she reported no prior history of being
4 diagnosed with ADHD. This is not indicative of an individual who suffers from ADHD in
5 adulthood, as the condition first emerges in childhood (and in most patients resolves by
6 adulthood). The patient also indicated in the questionnaire that she used methamphetamine¹⁴ off
7 and on. Respondent did not document whether the patient was actively using methamphetamine
8 during the time she was receiving care from him or whether he had considered the impact of the
9 patient's history of methamphetamine in reaching his diagnosis of ADHD.

10 49. Respondent prescribed P-6 multiple benzodiazepines¹⁵ concurrently, the prescriptions
11 for which she filled early. The benzodiazepines prescribed by Respondent also overlapped with
12 those prescribed by other providers. For example, on May 21, 2015, P-6 filled a prescription
13 written by Respondent for Ativan¹⁶ 1 mg, dispense 60 for a 15-day supply, which corresponds to
14 4 mg daily, a high dose. Just eight days later, on May 29, 2015, P-6 filled a prescription by
15 another provider for the benzodiazepine Xanax¹⁷ 2 mg dispense 60 for a 30-day supply, which is
16 4 mg daily and a high dose. Then, four days later, on June 2, 2015, P-6 filled a prescription by
17 Respondent for Ativan 1 mg dispense 60 for a 15-day supply. Ten days later, on June 12, 2015,
18 P-6 filled a prescription by Respondent for the benzodiazepine Klonopin 1 mg dispense 60 for a
19 15-day supply, which is 4 mg daily and is again a high dose. Then, on June 16, 2015, P-6 filled a
20 ///

21
22 ¹⁴ Methamphetamine is a powerful, highly addictive stimulant that affects the central
23 nervous system. It is a Schedule II controlled substance under Health and Safety Code section
24 11055, subdivision (d)(2), and a dangerous drug as defined in Business and Professions Code
25 section 4022.

26 ¹⁵ Benzodiazepines are a controlled substance pursuant to Health and Safety Code section
27 11057, subdivision (d), and a dangerous drug as defined in Business and Professions Code section
28 4022.

¹⁶ Lorazepam (Ativan®), a benzodiazepine, is a centrally acting hypnotic-sedative. It is a
Schedule IV controlled substance under Health and Safety Code section 11057, subdivision
(d)(16), and a dangerous drug as defined in Business and Professions Code section 4022.

¹⁷ Alprazolam (Xanax®), a benzodiazepine, is a centrally acting hypnotic-sedative. It is a
Schedule IV controlled substance under Health and Safety Code section 11057, subdivision
(d)(1), and a dangerous drug as defined in Business and Professions Code section 4022.

1 prescription by Respondent for Ativan 1 mg dispense 60 for a 15-day supply. Then, six days later,
2 on June 22, 2015, she filled another Xanax prescription by another provider of 2 mg dispense 60
3 for a 30-day supply.

4 50. Respondent also prescribed P-6 multiple stimulants concurrently. For example, on
5 May 1, 2015, P-6 filled a prescription by Respondent for Metadate ER¹⁸ 20 mg dispense 90 for a
6 30-day supply, which equates to a daily dose of 60 mg. This was concurrent with a prescription
7 for Adderall¹⁹ 10 mg dispense 60 for a 30-day supply. In addition, Respondent concurrently
8 prescribed P-6 very similar stimulant medications with the same active ingredient. For example,
9 on May 20, 2015, P-6 filled a prescription of Concerta²⁰ 36 mg dispense 30 for a 30-day supply
10 written by Respondent. Then, three days later, March 23, 2015, P-6 filled another prescription by
11 Respondent for Metadate ER (methylphenidate) 20 mg, dispense 90 for a 30-day supply.

12 51. Respondent also prescribed the patient opiates like oxycodone for her pains.

13 52. In a letter by P-6 dated June 18, 2016, she reported emotional distress and not being
14 able to focus or concentrate. This is not indicative of an individual who was responding to
15 treatment. Rather, the letter suggests that P-6 had likely developed tolerance and withdrawal to
16 the benzodiazepines and stimulants that she was prescribed.

17 53. Respondent's failure to maintain adequate records of his treatment of P-6 was an
18 extreme departure from the standard of care. His progress notes are illegible, and the legible
19 documents among his records do not provide a complete account of his treatment, including the
20 basis for his assessment, the treatment offered, and the reasoning supporting his treatment.

21 54. Respondent's unsupported diagnosis of the patient with ADHD was a departure from
22 the standard of care.

23 ¹⁸ Methylphenidate (Metadate,® Concerta,® Ritalin®) is a stimulant used to treat ADHD
24 and narcolepsy. It is a Schedule II controlled substance under Health and Safety Code section
25 11055, subdivision (d)(6), and a dangerous drug as defined in Business and Professions Code
section 4022.

26 ¹⁹ Adderall® is brand name for a drug containing a combination of amphetamine and
27 dextroamphetamine, central nervous system stimulants that affect chemicals in the brain and
28 nerves that contribute to hyperactivity and impulse control. It is used to treat narcolepsy and
ADHD. It is a Schedule II controlled substance under Health and Safety Code section 11055,
subdivision (d)(1), and a dangerous drug as defined in Business and Professions Code section
4022.

²⁰ Concerta® is a brand name of methylphenidate, described above, at footnote 18.

1 **SECOND CAUSE FOR DISCIPLINE**

2 **(Repeated Negligent Acts)**

3 57. Respondent is subject to disciplinary action under section 2234, subdivision (c), of
4 the Code, because he engaged in repeated negligent acts in the care and treatment of patients.
5 These acts include those alleged in the First Cause for Discipline, as well as the following, as
6 alleged above:

- 7 A. Respondent failed to maintain adequate records of his treatment of P-1;
- 8 B. Respondent diagnosed P-1 with "Pain Disorder," without documenting any
9 evaluation of the patient's pain and without specifying whether its etiology was
10 psychological, physical, or both;
- 11 C. Respondent continued prescribing Ambien to P-1 despite warning signs of her
12 addiction to it, and he failed to document taking steps to address her potential
13 addiction or to justify his continued prescribing;
- 14 D. Respondent failed to justify the risks of the medication regimen he continued to
15 prescribe to P-2, despite the patient's lack of response to the medication, and he
16 ceased prescribing an antidepressant medication for the patient's Major
17 Depressive Disorder;
- 18 E. Respondent diagnosed P-3 with "Pain Disorder," without documenting any
19 evaluation of the patient's pain and without specifying whether its etiology was
20 psychological, physical, or both;
- 21 F. Respondent prescribed excessive amounts of Ambien to P-3 despite warning signs
22 of his addiction to it, and he failed to document taking steps to address P-3's
23 potential addiction and to justify his continued prescribing;
- 24 G. Respondent failed to maintain adequate records of his treatment of P-5; and
- 25 H. Respondent did not provide a basis for his diagnoses of P-6 with ADHD.

26 ///

27 ///

28 ///

